
What We’re Reading: FDA Panel Supports Pfizer Vaccine in Children; Merck Grants COVID-19 Pill License; Infections Down by 60%
An FDA advisory panel voted 17-0 in favor of the Pfizer COVID-19 vaccine for children aged 5 to 11 years; COVID-19 pill molnupiravir to be manufactured and sold in 105 developing nations; new US COVID-19 cases dropped nearly 60% in just over a month.
FDA Panel Votes to Authorize Pfizer COVID-19 Vaccine for Children 5 to 11 Years
A FDA advisory panel voted in favor of authorizing the Pfizer-BioNTech COVID-19 vaccine for children aged 5 to 11 years,
Merck Grants Royalty-Free License for COVID-19 Pill to Developing Countries
Merck granted a royalty-free license for its COVID-19 pill, molnupiravir, allowing the drug to be manufactured and sold cheaply in 105 developing nations,
New US COVID-19 Infections Down by 60%
According to data compiled by
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.